Status:

COMPLETED

A Study of NBL-012 in Healthy Chinese Subjects

Lead Sponsor:

NovaRock Biotherapeutics, Ltd

Conditions:

Healthy Subjects

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

This is a phase 1, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the safety, tolerability and pharmacokinetics (PK) of NBL-012 as single ascending doses (SAD) admin...

Detailed Description

This is a phase 1, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the safety, tolerability and pharmacokinetics of NBL-012 administered subcutaneously as single asce...

Eligibility Criteria

Inclusion

  • Healthy male and/or female subjects between the ages of 18 and 45 years (inclusive) at screening.
  • Body Mass Index (BMI) of 18 to 26 kg/m2 (inclusive), body weight for male ≥50 kg and for female≥45 kg.
  • Good general health defined as no clinically significant abnormalities identified by a detailed medical history (thoracic and abdominal examination, nervous and mental system examination, etc.), full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG,

Exclusion

  • Participated in any drug or medical device clinical trial within 3 months before screening
  • Pregnant or nursing (lactating) women who have a positive blood/urine pregnancy test.
  • Females of child-bearing potential (defined as all females physiologically capable of becoming pregnant) and males who are unwilling or unable to use effective contraception during the study and until the end of study visit (more than 15 weeks after drug administration), or subjects with a plan to give birth wi

Key Trial Info

Start Date :

July 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 23 2022

Estimated Enrollment :

52 Patients enrolled

Trial Details

Trial ID

NCT05259189

Start Date

July 1 2021

End Date

May 23 2022

Last Update

July 20 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital of Soochow University.

Suzhou, Jiangsu, China, 215006